<DOC>
	<DOC>NCT01440595</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3) hepatitis C virus (HCV) infections.</brief_summary>
	<brief_title>Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Body weight ≥ 88 lbs and ≤ 275 lbs Documented chronic Hepatitis C (CHC) GT2 or GT3 infection No known cirrhosis Agrees to use two acceptable methods of birth control during study and through 6 months after last dose of study drug Chest Xray within the last 6 months Eye exam within the last 6 months Known to be human immunodeficiency virus (HIV) positive or coinfected with active hepatitis B virus (positive for Hepatitis B surface antigen) Prior approved or investigational treatment for hepatitis C Evidence of hepatocellular carcinoma Diabetic and/or high blood pressure with clinically significant eye exam findings Preexisting psychiatric condition Clinical diagnosis of abuse of certain substances within specified timeframes Known medical condition that could interfere with participation Active or suspected cancer within the last 5 years Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs Male who is planning to impregnate partner or donate sperm Male with a pregnant female partner Chronic hepatitis not caused by HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>